

Anti-*Toxoplasma* Activities of Antiretroviral Drugs and Interactions with Pyrimethamine and Sulfadiazine In Vitro

FRANCIS DEROUIN* AND MAUD SANTILLANA-HAYAT

Laboratoire de Parasitologie-Mycologie, Faculté de Médecine—Hôpital Saint-Louis, 75006 Paris, France

Received 20 March 2000/Returned for modification 15 May 2000/Accepted 8 June 2000

The anti-*Toxoplasma* activities of nine antiretroviral drugs were examined in vitro. Nucleoside analogs had no effect on parasite growth, whereas ritonavir and nelfinavir were inhibitory for *Toxoplasma*, with 50% inhibitory concentrations of 5.4 and 4.0 $\mu\text{g/ml}$, respectively. None of the antiviral drugs affected the anti-*Toxoplasma* activity of pyrimethamine or sulfadiazine.

In human immunodeficiency virus (HIV)-infected patients, the recommended treatment or prophylaxis for toxoplasmic encephalitis is a combination of a sulfonamide and a dihydrofolate reductase inhibitor (8, 13). An additional therapeutic benefit can also be expected from antiretroviral therapy through the restoration of host antimicrobial immunity. However, one study showed that azidovudine (AZT) negatively interfered with the antiparasitic effect of pyrimethamine (7); in contrast, didanosine (ddI) was found to have in vitro and in vivo activity against *Toxoplasma gondii* (12). Thus, our objective was to extend these studies by testing the anti-*Toxoplasma* activities of five nucleoside analogs and four protease inhibitors and their possible in vitro interaction with pyrimethamine and sulfadiazine, as first-line anti-*Toxoplasma* drugs.

We used tachyzoites of the virulent RH strain of *T. gondii*. Tissue cultures and drug tests were carried out using MRC5 fibroblast tissue cultures as previously described, with quantification of *Toxoplasma* growth by enzyme-linked immunosorbent assay (ELISA) (4). The following drugs were tested: AZT, lamivudine, ddI, stavudine, zalcitabine, ritonavir, indinavir, nelfinavir, and saquinavir. Stock solutions (10 mg/ml) were prepared in distilled water, except for ritonavir, which was dissolved in methanol, and saquinavir, which was dissolved in 50% methanol–50% acetone. Pyrimethamine and sulfadiazine (Sigma) were dissolved at 1 mg/ml in 50% methanol–50% acetone. Serial dilutions were then prepared in culture medium. Each antiviral drug was tested at serial concentrations ranging from 5×10^{-5} to 100 $\mu\text{g/ml}$ (final concentration). Each concentration was tested in eight replicate wells and in two replicate culture plates. For assessing the interaction between drugs, combinations of three concentrations of each antiparasitic drug and four concentrations of each antiviral drug were tested in a two-dimensional test. From the results of previous experiments (4) and from individual tests of antiviral drugs, we selected concentrations that resulted in a range of inhibition from noninhibitory to completely inhibitory. For antiviral drugs that had no anti-*Toxoplasma* activity, we selected the highest concentration that was found to be nontoxic for the monolayer and three fivefold dilutions of this concentration. Each experiment used two or three replicate plates in which each drug or drug combination was tested in four replicate wells. All experiments were repeated twice. The effect of each drug at various concentrations was described by plotting

the optical density (OD) values generated by the ELISA as a function of the logarithm of the concentration. A linear regression model was used to summarize the concentration-effect relationship and to determine the 50% inhibitory concentration (IC_{50}). The effect of the drugs in combination was tested by using a two-way analysis of variance which included the estimation of an interaction factor (4).

ddI, zalcitabine, stavudine, and lamivudine had no inhibitory effect on *Toxoplasma* growth, and no toxicity to the monolayers was observed by microscopic examination. With AZT and indinavir, an inhibitory effect was noted at 100 $\mu\text{g/ml}$ without significant toxicity to the host cells (Fig. 1A and B). Saquinavir was inhibitory at concentrations of ≥ 20 $\mu\text{g/ml}$, which were also found to be toxic for the monolayers. Ritonavir and nelfinavir were inhibitory for *Toxoplasma* at concentrations of < 10 $\mu\text{g/ml}$ (Fig. 1C and D). Both ritonavir and nelfinavir were noninhibitory at concentrations of ≤ 2 $\mu\text{g/ml}$, and a marked increase of the inhibitory effect was observed with between 2 and 10 $\mu\text{g/ml}$, the concentration at which *Toxoplasma* growth was completely inhibited. A toxic effect on the monolayers was noted with nelfinavir at 20 $\mu\text{g/ml}$ and with ritonavir at 40 $\mu\text{g/ml}$. The IC_{50} s were estimated to be 5.4 $\mu\text{g/ml}$ (95% confidence interval, 4.5 to 6.9 $\mu\text{g/ml}$) for ritonavir and 4.0 $\mu\text{g/ml}$ (95% confidence interval, 3.4 to 5.2 $\mu\text{g/ml}$) for nelfinavir.

With the two-way analysis of variance that was used for assessing the drug combinations, the effect of each drug and the interaction effects of drugs in combination were estimated, taking into account the individual effect of each drug as well as the intra- and interplate variability. The synergistic effect of the combination of pyrimethamine with sulfadiazine was confirmed (Table 1), and combinations of one of the antiretroviral drugs with pyrimethamine or sulfadiazine were analyzed. For all combinations tested, there was no significant interaction

TABLE 1. Inhibitory effect of pyrimethamine combined with sulfadiazine

Concn of sulfadiazine ($\mu\text{g/ml}$)	OD value (10^3) at the indicated pyrimethamine concn ($\mu\text{g/ml}$) ^a			
	0	0.01	0.05	0.5
0	838 \pm 60	855 \pm 65	679 \pm 70	73 \pm 23
0.02	756 \pm 74	819 \pm 32	233 \pm 51*	42 \pm 27
0.2	393 \pm 54	140 \pm 39*	26 \pm 14*	15 \pm 14*
2	37 \pm 9	18 \pm 11	14 \pm 13	14 \pm 6

^a Mean \pm standard deviation; each value represents the results from 8 to 12 replicate wells from 2 or 3 replicate plates. *P* values were calculated for the interaction effect. *, *P* < 10^{-4} .

* Corresponding author. Mailing address: Laboratoire de Parasitologie-Mycologie, Faculté de Médecine—Hôpital Saint-Louis, 15 rue de l'École de Médecine, 75006 Paris, France. Phone: 33 1 43 29 65 25. Fax: 33 1 43 29 51 92. E-mail: paracord@wanadoo.fr.




FIG. 1. In vitro effect of antiviral drugs on *T. gondii* growth in MRC5 tissue culture. Each graph shows the OD value ($\times 1,000$) from ELISA with infected monolayers (y axis) versus drug concentration (x axis) for AZT (A), indinavir (B), ritonavir (C), and nelfinavir (D).

effect. Drugs that individually had no inhibitory effect against *T. gondii* did not alter or enhance the anti-*Toxoplasma* activity of sulfadiazine or pyrimethamine. When antiretroviral drugs that were found to have an inhibitory effect on *T. gondii* were

combined with pyrimethamine or sulfadiazine, an additional but not synergistic effect resulted (Tables 2 and 3). We conclude that these antiviral drugs had no interaction effect in vitro on the anti-*Toxoplasma* activity of pyrimethamine or sul-

TABLE 2. Inhibitory effect of AZT and indinavir, combined with sulfadiazine or pyrimethamine

Drug and concn ($\mu\text{g/ml}$)	OD value (10^3) at indicated drug concn ($\mu\text{g/ml}$) ^a									
	AZT					Indinavir				
	0	1	5	25	100	0	1	5	25	100
Sulfadiazine										
0	630 \pm 106	642 \pm 131	626 \pm 97	648 \pm 78	376 \pm 103	734 \pm 86	762 \pm 97	692 \pm 71	654 \pm 107	287 \pm 85
0.02	512 \pm 91	523 \pm 103	554 \pm 97	537 \pm 81	309 \pm 77	605 \pm 111	666 \pm 55	637 \pm 122	624 \pm 114	254 \pm 91
0.2	209 \pm 51	172 \pm 40	201 \pm 45	169 \pm 45	135 \pm 27§	188 \pm 92	284 \pm 122	400 \pm 116	249 \pm 107	62 \pm 31§
2	31 \pm 26	27 \pm 15	30 \pm 20	27 \pm 20	27 \pm 19	28 \pm 18	42 \pm 30	36 \pm 16	26 \pm 20	31 \pm 21
Pyrimethamine										
0	932 \pm 104	1,013 \pm 75	989 \pm 109	898 \pm 145	743 \pm 83	697 \pm 143	813 \pm 120	837 \pm 84	837 \pm 90	330 \pm 32
0.01	959 \pm 104	1,062 \pm 105	927 \pm 106	908 \pm 112	703 \pm 82	643 \pm 136	755 \pm 110	800 \pm 164	791 \pm 122	339 \pm 56
0.05	706 \pm 84	702 \pm 52	666 \pm 97	679 \pm 57	587 \pm 65§	552 \pm 38	603 \pm 86	745 \pm 112	795 \pm 103	250 \pm 51§
0.25	100 \pm 36	107 \pm 65	92 \pm 50	92 \pm 19	81 \pm 22	80 \pm 40	79 \pm 16	76 \pm 11	78 \pm 29	84 \pm 29

^a Each value represents the results from 8 to 12 replicate wells from 2 or 3 replicate plates. *P* values were calculated for the interaction effect. §, additive but not synergistic effect (*P* > 0.05).

TABLE 3. Inhibitory effect of ritonavir and nelfinavir, combined with sulfadiazine or pyrimethamine

Drug and concn ($\mu\text{g/ml}$)	OD (10^3) at indicated drug concn ($\mu\text{g/ml}$) ^a									
	Ritonavir					Nelfinavir				
	0	1	2	5	25	0	0.5	2	5	10
Sulfadiazine										
0	633 \pm 43	611 \pm 50	596 \pm 49	472 \pm 38	33 \pm 16	762 \pm 128	810 \pm 87	767 \pm 73	423 \pm 133	80 \pm 113
0.02	632 \pm 34	631 \pm 88	632 \pm 63	463 \pm 43	29 \pm 12	695 \pm 62	754 \pm 109	690 \pm 64	454 \pm 106	15 \pm 11
0.2	421 \pm 77	455 \pm 99	555 \pm 39	383 \pm 63	14 \pm 13§	264 \pm 69	370 \pm 84	526 \pm 109	556 \pm 95	14 \pm 12§
2	14 \pm 11	52 \pm 25	31 \pm 17	64 \pm 75	6 \pm 6§	14 \pm 12	31 \pm 23	38 \pm 29	57 \pm 30	24 \pm 16
Pyrimethamine										
0	705 \pm 58	766 \pm 107	756 \pm 105	628 \pm 47	32 \pm 29	821 \pm 77	855 \pm 65	842 \pm 67	578 \pm 190	15 \pm 17
0.01	672 \pm 128	830 \pm 115	854 \pm 128	614 \pm 43	24 \pm 17	764 \pm 69	819 \pm 32	808 \pm 65	625 \pm 106	9 \pm 7
0.05	595 \pm 69	543 \pm 120	607 \pm 55	500 \pm 45	15 \pm 17§	603 \pm 48	565 \pm 80	560 \pm 50	583 \pm 97	10 \pm 8
0.25	120 \pm 35	83 \pm 50	105 \pm 32	75 \pm 44	17 \pm 16§	11 \pm 9	25 \pm 14	16 \pm 15	29 \pm 23	11 \pm 8

^a Each value represents the results from 8 to 12 replicate wells from 2 or 3 replicate plates. *P* values were calculated for the interaction effect. §, additive but not synergistic effect (*P* > 0.05).

fadiazine. In particular, we found no antagonistic effect between AZT and pyrimethamine, as had been previously reported by Israelski et al. (7), and this was confirmed with four other nucleoside analogs.

Our study revealed that several antiretroviral drugs were inhibitory for *T. gondii*. In contrast to Sarciron et al. (12), we found no inhibitory effect with ddI at concentrations up to 100 $\mu\text{g/ml}$. There is no clear explanation for this discrepancy, except that we used a more virulent strain of *T. gondii* and that cultures were prepared with fibroblasts instead of phagocytic THP1 cells. We found that ritonavir and nelfinavir were highly inhibitory for *Toxoplasma* growth, with IC_{50} s of 5.4 and 4.0 $\mu\text{g/ml}$, respectively (i.e., concentrations that can be achieved in humans [5, 6, 9, 10]). The mode of action of HIV protease inhibitors on *T. gondii* remains to be elucidated. Indeed, several proteases already have been found in protozoa (3, 11), but evidence of the target enzyme of HIV protease inhibitors, i.e., aspartyl protease, has not yet been found in *T. gondii*. Our data suggest that this enzyme is present in *T. gondii* and that it plays a role in parasitic replication. Recent data showing that aspartyl protease is also present in fungi and can be inhibited by anti-HIV protease inhibitors (1, 2) also indicate that this enzyme could be a target for various microorganisms. In these other two studies, ritonavir was a potent inhibitor of *Candida albicans* and *Pneumocystis carinii*, as we found in this study for *T. gondii*. In addition to this direct pharmacological effect on parasitic growth, ritonavir and nelfinavir also may have an indirect effect on the host cell through enhancement of the respiratory burst of neutrophils (D. Ghanimi, A. Perianin, J. Morini, M. Levacher, I. Florentin, J. Giroud, and B. Rouveix, Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1831, 1999). This mechanism could be of particular importance for an intracellular parasite such as *T. gondii*.

REFERENCES

- Atzori, C., E. Angeli, A. Mainini, F. Agostoni, V. Micheli, and A. Cargnel. 2000. In vitro activity of human immunodeficiency virus protease inhibitors against *Pneumocystis carinii*. *J. Infect. Dis.* **181**:1629–1634.
- Cassone, A., F. De Bernadis, A. Torosantucci, E. Tacconelli, M. Tumbarello, and R. Cauda. 1999. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. *J. Infect. Dis.* **180**:448–453.
- Conseil, V., M. Soète, and J. F. Dubremetz. 1999. Serine protease inhibitors block invasion of host cells by *Toxoplasma gondii*. *Antimicrob. Agents Chemother.* **43**:1358–1361.
- Derouin, F., and C. Chastang. 1989. In vitro effects of folate inhibitors on *Toxoplasma gondii*. *Antimicrob. Agents Chemother.* **33**:1753–1759.
- Flexner, C. 1998. HIV protease inhibitors. *N. Engl. J. Med.* **338**:1281–1292.
- Gatti, G., A. Di Biagio, R. Casazza, C. De Pascalis, M. Bassetti, M. Cruciani, S. Vella, and D. Bassetti. 1999. The relationship between ritonavir plasma levels and side-effects: implication for therapeutic drug monitoring. *AIDS* **13**:2083–2089.
- Israelski, D. M., C. Tom, and J. S. Remington. 1989. Zidovudine antagonizes the action of pyrimethamine in experimental infection with *Toxoplasma gondii*. *Antimicrob. Agents Chemother.* **33**:30–34.
- Luft, B. J., and J. S. Remington. 1992. Toxoplasmic encephalitis. *Clin. Infect. Dis.* **15**:211–222.
- Merry, C., M. G. Barry, F. Mulcahy, M. Ryan, J. Heavey, J. F. Tjia, S. E. Gibbons, A. M. Breckenridge, and D. J. Back. 1997. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. *AIDS* **11**:F29–F33.
- Pai, V. B., and M. C. Nahata. 1999. Nelfinavir mesylate: a protease inhibitor. *Ann. Pharmacother.* **33**:325–339.
- Rosenthal, P. J. 1999. Proteases of protozoan parasites. *Adv. Parasitol.* **43**:105–159.
- Sarciron, M.-E., P. Lawton, C. Saccharin, A.-F. Petavy, and F. Peyron. 1997. Effects of 2',3'-dideoxyinosine on *Toxoplasma gondii* cysts in mice. *Antimicrob. Agents Chemother.* **41**:1531–1536.
- USPHS/IDSA Prevention of Opportunistic Infections Working Group, Infectious Diseases Society of America. 1999. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. *Ann. Intern. Med.* **131**:873–908.